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Abstract
Background: Desmoid-type fibromatosis (DF) is a aggressive (myo)fibroblastic neoplasm with an infiltrative growth
and a tendency to local recurrence. Resection of the tumour and/or radiation were proposed as principal treatment.
The aim of this retrospective study was to analyze the local control rates focusing on the effect of surgical margins
and radiotherapy.
Methods: From 1981 to 2014, 44 patients had been treated. Fifty four therapies had been applied, in 50 cases
surgery +/− radiation therapy, NSAIDs or chemotherapy. In 4 cases a conservative approach was chosen. Thirty
seven patients had primary, 17 recurrent disease. Endpoint was either local recurrence (LR), progression of residual
disease or rare non-metastatic secondary lesions at the same extremity.
Results: The mean age was 39,4 years. In 17 cases a R0, in 27 a R1 and in 6 cases a R2 resection was achieved. Four
patients were treated conservatively. All together in 21 cases radiotherapy, in 5 NSAIDs, in 3 imatinib and in 2 cases
each tamoxifen or chemotherapy had been applied. The median follow-up was 119 months. 5-year recurrence free
survival after resection was 78%. 10 (20.4%) patients developed LR between 5 and 42 months after therapy.
Recurrent disease was a negative factor on LR. Margins, radiotherapy, sex, or size of the tumour had no significant
impact on LR. Patients younger than 40 years had a significant higher risk of LR.
Conclusions: Surgical margins are less important than keeping function. Radiotherapy might be an option in
unresectable lesions, the role of adjuvant radiotherapy is controversially discussed.
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Background
Desmoid-type fibromatosis (DF) is defined by the World
Health Organization (WHO) as a locally aggressive (myo)fi-
broblastic neoplasm arising usually in deep soft tissues with
an infiltrative growth and a tendency to local recurrence,
but a lack of metastatic potential. [1] The incidence is esti-
mated 2.1–5.4 per million people per year increasing in
both locations, extra-abdominal and in the abdominal wall.
[2] There are two group of patients with prognosis quite
different between both. Patients there DF is associated with
the autosomal dominant familial adenomatous polyposis
(FAP) syndrome characterized by a germline mutation of
the adenomatous polyposis coli (APC) gene and a risk of
30% developing DF and patients with sporadic DF (harbor-
ing the CTNNB1 mutation (beta-catenin) in the tumor,
which are considered mutually exclusive. [3]
DF are most often seen between 16 and 60 years of
age twice as common in female than male patients. [4]
Extra abdominal Desmoid fibromas can affect any ana-
tomical region but are most common in the limb or the
limb girdle (50%), the trunk (43%) or the head and neck
region (7%). [5] 10% of cases had been described as
multifocal. [6]
In former years resection of the tumour and/or radi-
ation were proposed as principal treatment. [7] Systemic
medical treatment including non-steroidal anti-
inflammatory drugs (NSAIDs), anti-estrogens, cytotoxic
chemotherapy, Interferon α or tyrosine kinase inhibitors
showed conflicting results. [8] With active surveillance
alone a spontaneous regression of 28–50% of cases in
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extra abdominal DF is observed thus interfering with
outcome data of any treatment studies. [4] Therefore the
European Sarcoma Network Working Group (ESNWG),
the European Organization for Research and Treatment
of Cancer (EORTC) and others consider an initial period
of active observation in extra abdominal DF as proposed
already more than a decade ago by some authors. [8–11]
The aim of this retrospective study was to analyze the
local control rates in a consecutive single-institution
series of surgically-treated patients focusing on the effect
of surgical margins and adjuvant radiotherapy in primary
and recurrent disease.
Methods
From 1981 to 2014, 44 consecutive patients with DF of
the extremities and trunk wall had been treated in our
institution. In those 44 patients in total 54 therapies had
been done, in 50 cases surgery +/− additional therapies
as radiation therapy, NSAIDs or chemotherapy. In 4
cases a conservative approach was chosen. All tumours
had a diagnosis of DF based on histological features and
immunohistochemistry. Thirty seven patients had pri-
mary, 17 recurrent disease. Five of the recurrences de-
veloped in 5 patients with primary resections included
also in this study. Seven patients had recurrences after
first treatment elsewhere. From those 7 patients 3 there
treated a second time for a further recurrence and one
for a second and third recurrence.
Preoperative staging included MRI (predominantly) or
CT of the tumour region. Tumour size was determined
by the greatest diameter of the tumour in preoperative
imaging. All patients underwent limb-sparing surgical
resection. The margin was defined as R0 if a rim of
sound tissue around the lesion was present (wide resec-
tion), R1 if the margins were contaminated by the
tumour (marginal resection) or R2 if remaining tumour
was evident (intralesional resection). In one case follow-
up could not be obtained. Fifty four cases were followed
routinely for evidence of local recurrence or secondary
lesions, also preferably with MRI.
For statistical analysis, overall and recurrence-free sur-
vival were calculated by the Kaplan-Meier method. Uni-
variate subgroup analysis was done using the log-rank
test (time-to-event data) or the chi-square test. For
multivariate analysis, a Cox proportional-hazard regres-
sion model was used. Significance analysis was per-
formed using the log-rank test, the Chi-Square test, or
the Cox proportional-hazards regression. The data ana-
lysis software used was MedCalc®.
Results
The patients details are described in Table 1. In 4 cases,
multiple lesions were evident. None of our patients had
FAP-associated disease but routine GI screening (colon-
oscopy) was not done.
The mean duration of symptoms in primary disease
was 13.2 months (range, 1–96), in recurrent cases
4.6 months (range, 1–12) n.s. 31 (62%) patients com-
plained of swelling, 29 (58%) of pain. Neurological im-
pairment (sensory) or restriction of movement was seen
occasionally.
In 17 cases a wide (R0) resection, in 27 a marginal
(R1) resection and in 6 cases an intralesional (R2) resec-
tion was achieved. Only one patient had a minor ampu-
tation (distal toe). In 4 patients (all recurrent tumours)
no resection but either radiotherapy, NSAIDs, imatinib
or NSAIDs/tamoxifen had been applied. All together in
21 cases radiation therapy, in 5 cases NSAIDs, in 3 cases
imatinib and in two cases each tamoxifen or cytotoxic
chemotherapy had been applied.
One patient with surgical resection was lost to follow-
up, leaving 49 resected and 4 conservative treated cases.
Two patient died in follow-up independent to the
tumour or therapy. The median follow-up was
119 months (range, 3–412). Only 2 patients had a
follow-up of less than 12 months. Over all 5-year recur-
rence free survival after resection was 78% (Fig. 1). In
total 10 (20.4%) patients developed local recurrences be-
tween 5 and 42 months after therapy.
Table 1 Patient characteristics
Number of patients 44
Sex 25 f, 19 m
Mean age (range) 39.4 y (14–69)
Number of treatments 54
Mean tumour size (range) 7.7 cm (1–25)
Tumour site n(%)
Upper limb 21 (39%)
shoulder 9
upper arm 7
lower arm 2
axilla 2
hand 1
Lower limb 19 (35%)
upper calf 7
lower calf 5
foot 6
knee 1
Trunk 8 (15%)
Pelvis 6 (11%)
Presentation
Primary 37 (69)
Recurrent 17 (31
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In every case the indication of adjuvant radiotherapy
was discussed in dependence to the achieved margins
and the approximity of functionally important struc-
tures. As shown in Table 2 recurrent disease was a nega-
tive factor on LR (Fig. 2; p = 0.0338). Of the 6 patients
with intralesional surgery, one was lost to follow-up.
One patient has a stable disease after radiation, another
2 patients also a stable disease without adjuvant therapy.
One patient is progressive, starting 2 years after surgery,
without further treatment, one patient is treated with
imatinib and chemotherapy for now 3 months.
In univariate analysis margins, radiotherapy, sex, or
size of the tumour did not show a significant impact on
local recurrence.
From 49 evaluable surgically treated cases 26 were
younger than 40 years. Those patients had a significant
higher risk of local recurrence (Fig. 3; p = 0.0104). Only
one patient in the group of patients older than 40 years
showed recurrent disease. In multivariate analysis (pri-
mary/recurrent, age < 40 years) only age kept signifi-
cance. (PD/RD p = 0.11, HR 2.80, CI 0.8–9.8; Age p =
0.0495, HR 8.0, CI 1.0–63).
From the 4 patients with conservative therapy only, all
had had recurrent disease. One is progressive after
radiotherapy, one shows stable disease for more than
8 years after initial NSAIDs, another one after imatinib
and the last patient has no evidence of disease after
NSAIDs and tamoxifen.
Discussion
Diagnosis and imaging in DF is well described. [4, 8]
Most of the cases of DF are sporadic. Metachronous or
synchronous multicentric disease is seen in up to 10% of
cases. [7] In the last years a number of clinical factors as
e.g. age, size and site had been identified for progression
free survival. [12] Despite being considered “benign”, DF
bears a considerable risk of local recurrence and func-
tional impairment. Surgical resection, which had been
the mainstay of therapy over a long period of time is as-
sociated with local recurrence rates as high as 19–75%,
but in most of the studies below 50%. [5, 7, 13–19] Re-
garding the margins which should be obtained there are
contradictory recommendations mainly based on institu-
tional experience. There are studies which prove a lower
rate of recurrent disease in R0 resected cases. [13, 19] In
a major review of the literature in 2004 by Leithner et a.
the authors included 12 studies with 412 primary and
127 recurrent cases. [20] In primary cases wide or
Fig. 1 Recurrence free survival after 49 resections for DF
Table 2 Summary of local recurrence in surgically treated patients
Total Primary Recurrent R0 R1 R2
-RTX + RTX - RTX + RTX -RTX + RTX -RTX + RTX -RTX + RTX
10/49 (20.4%) 4/24 1/13 1/6 4/6 2/12 (16.7%) 1/5 (20%) 3/14 (21.4%) 4/13 (30.8%) 0/4 (1 Progression) 0/1
5/37(13.5%) 5/12 (41.7%)
p = 0.0374 n.s. n.s. n.s.
RTX Radiotherapy, R0, R1, R2 Resection margin
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radical resections showed a recurrence rate of 27%, in
marginal or intralesional cases 72% developed local re-
currences (p < 0.001). In recurrent cases the numbers
were 49 and 88% respectively (p < 0.001). Four years later
a second metaanalysis with the same focus was pub-
lished. [21] From 17 studies a significant effect of margin
on recurrence was seen in 7, a trend in 5, and in 5 stud-
ies marginal status did not affect the local recurrence
rate as e.g. 23% for R0 vs. 26% for R1 in primary resec-
tions. [22] So our own results of 18% for R0 and 26% for
R1 resections fit well into this scheme as also published
in more recent studies. [18] Most impressive was the
high frequency of further recurrences in recurrent dis-
ease in this study (42%). As shown above this is a well
known fact as described in the metaanalysis by Leithner
et al. Even in wide or radical resections in those patients
49% recurred. There are a number of studies coming to
the same conclusion [15, 17] but there are also conflict-
ing results. [13, 23] Identical recurrence rates of 33% are
reported in 85 primary and 104 recurrent cases [24]
whereas others even found a positive trend of local re-
currence with 75% after primary 53% after first and 50%
after second recurrence. [25] But as for the majority of
the literature a surgical approach in recurrent disease
Fig. 2 Recurrence free survival in 37 primary and 12 recurrent resections (p = 0.0338)
Fig. 3 Recurrence free survival in 26 resections in patients <40 years and 23 resections in patients >40 years (p = 0.0104)
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should be avoided. In addition in some of the reviewed
studies margins at all lost significance in multivariate
analysis. The authors conclude, that functionally disab-
ling operations to obtain negative margins should in any
cases be avoided.
Younger age seems to deteriorate the results as also
shown in this study. [13, 18] Shin et al. described in 60 pa-
tients younger than 38 years local recurrence as 40% vs
16% in patients older than 38 years. [15] Patients age older
than 37 years proved to be statistically associated with lon-
ger progression free survival as shown by Salas et al. [12]
Interestingly the authors state that the identification of
biologic pathways involved in the tumorigenesis of des-
moids emphasized these age differences, genomic alter-
ations being more common in older patients. [26]
Radiotherapy has a major role in the treatment of soft
tissue sarcomas. But as surgery, this is not as clear in
DF. A major problem in most of the retrospective stud-
ies, as in ours, is a mixing of patients with different pre-
sumed risk factors in irradiated and not irradiated
treatment groups. Especially margin status, as described
above an itself debatable prognostic factor, is interfering
strongly with radiation data. Striking in our study was
the high recurrence rate of 4/6 patients irradiated after
recurrent disease as compared to 1/13 in primary dis-
ease. The role of radiotherapy in DF management re-
mains controversial and is extensively debated. [27]
Ballo et al. showed a 10-year recurrence rate of 23% with
combination of surgery and radiotherapy and 31% with
radiotherapy alone (n.s.). [28] A dose of 50 Gy was associ-
ated with a 60% relapse rate, whereas higher doses yielded a
23% relapse rate (p < 0.05). This effect was also seen in a
larger retrospective multicenter review. [29] In a second
publication Ballo et al. showed a 10-year recurrence rate of
54% with surgery alone in R1 resected patients, 27% in R0
resected patients, 25% in combination of surgery and radio-
therapy and 24% with radiotherapy alone. [24] Spear et al.
reported an overall recurrence rate of 31% in surgery
treated patients alone vs. 28% combined with radiation
(n.s.). [30] In 23 R0 resections they showed a trend for
lesser recurrence with additional radiation (22% vs. 44%)
but without significance. Other authors failed, as in our
series, to demonstrate any significant benefit of adjuvant
radiotherapy, even accounting for margin status. [5, 13, 21–
23, 31] In a review of 22 studies by Nuyttens et al., in 2000,
in 234 patients treated with surgery alone and 80 patients
treated with radiotherapy alone, local recurrence was 39%
vs 22% (p = 0.023). [32] As described by Shin et al. or Hou-
dek et al. adjuvant radiotherapy delayed the recurrence of
the tumour without having an effect on the ultimate relapse
rate. [15, 33] In a retrospective multicentric European re-
view of 110 patients local recurrence in surgery only was
32% vs. 25% after combined treatment. Local progression
free survival proved to be better in combination (p < 0.001).
[29] In a prospective EORTC and ROG study published in
2013 44 patients received 56 Gy. [34] 10 patients (23%) de-
veloped local progression, 5 patients developed new lesions.
Based on the specific growth pattern, field definition is crit-
ical. In 6 recurring patients after radiation therapy only one
patient had a true in-field recurrence. [35] In another 17
patients, 7 recurrences were seen at the field border. [29]
The impact of radiotherapy in the treatment of desmoid tu-
mours remains hence unclear. Considering adjuvant radio-
therapy, the data is even less clear. Functional
complications after radiotherapy are well known, due to the
in general unimpaired life expectancy in DF also radiation-
induced malignancies should be considered. [36]
In the last years, a watchful “Wait-and-See” policy has
been advocated by many authors. In a retrospective sur-
vey on 55 patients Briand et al. described a 85% spon-
taneous growth arrest. [37] Half of the tumours were
stabilized at 1 year, one case increased continuously be-
yond 3 years, 2 patients showed a regrowth. In 20 pa-
tients treated with surveillance only, after median
35 months one complete and 5 partial regressions and
13 stable diseases were seen. Only one patient pro-
gressed needing surgery. [38] In a retrospective study of
109 patients initially treated by observation, 51 required
interventions as they progressed. [39]
So a more conservative approach seems to be justified
and is at the moment part of prospective trials or
current treatment guidance. [4, 8]
Conclusion
In summary DF has a high rate of recurrence. As pub-
lished in the last years spontaneous growth arrest or
even regression of the tumour are in numbers compar-
able to the effect of surgical resections. If surgery is ne-
cessary, surgical margins are less important than keeping
function for the patient. There was no difference be-
tween R0 and R1 resections in Local recurrence free sur-
vival. Other treatment modalities should be preferred
over surgery when DF ultimately recurs.
Definitive radiation might be an option in unresectable
progressive lesions, the role of adjuvant radiotherapy is
controversially discussed. Younger age and recurrent
disease seem to increase the risk of (further) local recur-
rence. A watchful “Wait-and-see” policy in primary le-
sions seems to be justified by the published data.
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